This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).

Inclusion Criteria:

1. Adult subjects (18-74 years old)

2. Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis).

3. Active uveitic disease as defined by the presence of at least 1 of the following parameters in at least 1 eye, as determined by the investigator:

   1. Active, inflammatory chorioretinal and/or retinal vascular lesion; OR
   2. ≥2+ vitreous haze grade (NEI/SUN criteria).

4. Receiving up to one non-corticosteroid, non-biologic, immunomodulatory therapy

5. Weight > 40 kg with a body mass index < 40 kg/m2.

Exclusion Criteria:

1. Has isolated anterior uveitis.

2. Has confirmed or suspected current diagnosis of infectious uveitis

3. History of:

   • Any lymphoproliferative disorder
   • Active malignancy;
   • History of cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.)

4. At risk of thrombosis and cardiovascular disease

5. Have a high risk for herpes zoster reactivation

6. Have active or recent infections

Other protocol defined Inclusion/Exclusion criteria may apply

Priovant Therapeutics will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) from eligible studies upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Data requests will be reviewed and approved on the basis of scientific merit.

The data will be made available within 24 months after study completion and will be accessible for a time frame appropriate for the approved proposal.

Access will be provided following review and approval of a research proposal and execution of a Data Sharing Agreement (DSA). Further details on Priovant Therapeutics' data sharing criteria and process for requesting access can be obtained by emailing info@priovanttx.com.